It is conceivable that SH3BP4 inactivation may contribute to an alternative Wnt activating mechanism in certain CRC subtypes, which could offer a new therapeutic strategy for targeting Wnt signaling in cancer. This evidence concerns the gene SH3BP4 and cancer.